Marksans Pharma Ltd on Monday announced that it has entered into a definitive agreement to acquire 100 per cent of the share capital of Netherlands-based QliniQ B.V., marking a strategic step in expanding its presence across regulated European markets.

The Mumbai-based pharmaceutical company said the acquisition would strengthen its forward-integration strategy through direct market-access capabilities in the European Union.

QliniQ is a profitable pharmaceutical company with established front-end sales, marketing and distribution capabilities across the Dutch healthcare market. The company operates a portfolio of niche pharmaceuticals and medical devices across women’s health, dermatology, respiratory care and other specialty segments.

Albert de Bruin and Raymond Lansink, board members and shareholders of QliniQ B.V., said, “We are delighted that QliniQ is becoming part of the Marksans Group. During our discussions with Marksans, we were particularly impressed by the Company’s strong track record in product development, its clear long-term vision, and its commitment to quality and innovation.”

They added, “Marksans has built strong product development capabilities, a broad and growing portfolio, and high-quality manufacturing expertise. Combining these strengths with QliniQ’s market presence and local expertise creates a compelling opportunity for future growth and value creation.”

Marksans Pharma Chairman and Managing Director Mark Saldanha said the acquisition would provide the company with direct access to the Netherlands market while enhancing its ability to commercialise products across regulated European markets.

“This acquisition represents an important strategic step in expanding Marksans’ presence across regulated European markets. QliniQ has built a profitable niche portfolio supported by established market access capabilities, long-standing customer relationships, and tender participation across the Netherlands healthcare ecosystem,” Saldanha said.

He added, “The acquisition provides Marksans with direct access to the Netherlands market and enhances our ability to commercialize existing and future products across regulated European markets. We believe this acquisition will strengthen our long-term growth opportunities and further enhance our global business.”

Marksans said the acquisition would provide it with established sales, marketing and distribution capabilities in the Netherlands, along with access to relationships with wholesalers, pharmacies, hospitals and health insurers.

The deal will also strengthen Marksans’ participation in insurer-led tender channels and provide access to EU GDP-compliant warehousing, wholesale distribution and regulatory infrastructure.

The company said the acquisition is expected to support commercialisation of its existing and future product portfolio in the Netherlands and strengthen its long-term presence across regulated European markets.

Published on June 1, 2026